PCNA and neoplasm: Moreover, AC-AFPK-IsCT1 treatment led to a reduction in the expression of the proliferation markers PCNA and Cyclin D1, resulting in a significant reduction in tumor cell proliferation as well as a decrease in mitochondrial membrane potential and an elevation in TNF-α expression without affecting normal cells.